Future outcome measures in MS

How will the definition of NEDA evolve? #MSBlog #MSResearch

"As promised the following is my presentation from a meeting I spoke at in Copenhagen yesterday. I covered NEDA and how I see its definition evolving in the future. This presentation explains why we replaced DAF (disease activity free) with NEDA (no evident disease activity); DAF implies we know everything about MS disease activity, whereas NEDA is a more humble term and allows us to adapt the definition as new technologies come online."

"My talk was very upbeat, particularly for people with progressive MS. The audience were very responsive to my proposed asynchronous model of progressive MS and the therapeutic lag hypothesis. As a result of these hypotheses I have given the odds of the fingolimod PPMS, siponimod SPMS, natalizumab SPMS and ocrelizumab PPMS trials being positive as being greater than 50% for each study; please note that according the the therapeutic lag hypothesis the odds of the studies being positive go up the longer the blinded phase of the trials run."




CoI: multiple; please note this meeting was hosted by Professor Per Soelberg Sorensen and his centre and sponsored by Biogen-Idec.

Labels: , , ,